Malawi delays reopening schools as cholera cases surge

2023-01-03
疫苗
BLANTYRE, Malawi, Jan 2 (Reuters) - Malawi has delayed the opening of public schools in the southern African country's two major cities of Blantyre and Lilongwe, the health minister said Monday, to try to slow down a surge in cholera deaths.
The total number of cases and deaths has accelerated to 17,824 and 595 respectively since cases were first reported in March, with the mortality rate increasing to 3.34 per cent, according to the Health Ministry.
Cholera is an annual problem during Malawi's rainy months from November to March, where the number of deaths is around 100 a year. But the current outbreak is expcted to be the worst yet.
"Due to the continuing increase of cholera cases and deaths in the cities of Blantyre and Lilongwe, primary and secondary schools in the two cities will not start on 3rd January as earlier advised," Health Minister Khumbize Chiponda said in a statement.
A new reopening date will be announced later, she said.
Malawi delays reopening schools as cholera cases surge
Preview
来源: Reuters
[1/3] Pilirani Wanja, a clinician at Ndirande Health Centre, demonstrates to clients how to take the cholera vaccine in response to the latest cholera outbreak in Blantyre, Malawi, November 16, 2022. REUTERS/Eldson Chagara
The global stockpile of cholera vaccines the World Health Organization helps manage is "currently empty or extremely low", a WHO official said last month amid a resurgence of the disease.
The U.N. agency said then there were around 30 countries around the world that had reported outbreaks in 2022, about a third higher than in a typical year.
Cholera is spread by contaminated food or water and can cause acute diarrhoea. Many people have mild symptoms but it can kill within hours if untreated.
Victims in Malawi include medics at public health centres.
Chiponda called on authorities to tighten control measures, including spraying chlorine to disinfect congested places such as markets and schools and stepping up inoculations.
Our Standards: The Thomson Reuters Trust Principles.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。